San Diego, CA -- (SBWIRE) -- 06/22/2021 -- An investor, who purchased NASDAQ: ACRX shares, filed a lawsuit over alleged violations of Federal Securities Laws by AcelRx Pharmaceuticals, Inc.

Investors who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 9, 2021. NASDAQ: ACRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Redwood City, CA based AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

On November 2, 2018, AcelRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") had approved DSUVIA for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments.

On February 16, 2021, AcelRx Pharmaceuticals, Inc disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, having "reviewed an 'SDS Banner Ad' (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display)," the FDA concluded that "[t]he promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA," and "[t]hus . . . misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative." The warning letter "request[ed] that AcelRx cease any violations of the FD&C Act" and "submit a written response to th[e] letter within 15 days from the date of receipt."

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) declined to as low as $1.02 per share on May 13, 2021.

The plaintiff claims that between March 17, 2020 and February 12, 2021, the defendants made false and/or misleading statements and/or failed to disclose that: AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA, that as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, that the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.